MarketArgan And 4 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Sep 27, 2024
MarketSarepta Therapeutics And 5 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Sep 20, 2024
MarketArgan And 6 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Sep 16, 2024
MarketKemper Corporation And 5 Other Stocks Have Very High Payout RatioVia News Editorial Team•Sep 8, 2024
MarketSilicon Motion Technology Corporation And 5 Other Stocks Have Very High Payout RatioVia News Editorial Team•Jun 22, 2024
MarketExtra Space Storage And 6 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Apr 6, 2024
MarketMeta Platforms And 4 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Apr 1, 2024
MarketArgan And 5 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Mar 12, 2024
MarketGlobal Indemnity Group, LLC, Natural Resource Partners LP Limited Partnership, Another 2 Companies Have A High Estimated Dividend YieldVia News Editorial Team•Mar 5, 2024
MarketArgan And 7 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Mar 1, 2024
MarketMFS Special Value Trust And 5 Other Stocks Have Very High Payout RatioVia News Editorial Team•Feb 22, 2024
MarketArgan And 6 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Feb 5, 2024
MarketIRSA Inversiones Y Representaciones S.A., MV Oil Trust Units Of Beneficial Interests, Another 7 Companies Have A High Estimated Dividend YieldVia News Editorial Team•Jan 28, 2024
MarketGenmab And 3 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Jan 20, 2024
MarketArgan And 7 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Jan 19, 2024
MarketArgan And 5 Other Stocks Have High Sales Growth And An Above 3% Return on EquityVia News Editorial Team•Jan 17, 2024